Alnylam Pharmaceuticals, Inc.

ALNYintermediary

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating disease by silencing the genes that cause it. Its ATTR franchise has established RNAi as a validated drug modality, and its deep pipeline across cardiometabolic, CNS, and infectious diseases promises to expand the platform's reach.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($2.4B)

静态数据（加载实时财务…）

ATTR Franchise (Amvuttra/Onpattro) (65%)

Royalties & Collaboration (Leqvio) (25%)

Other Pipeline Revenue (10%)

业务板块构成与主要客户

产品详情

Onpattro (Patisiran)30%

First FDA-approved RNAi therapeutic for hereditary ATTR amyloidosis

Amvuttra (Vutrisiran)40%

Subcutaneous RNAi treatment for ATTR polyneuropathy (quarterly dosing)

Leqvio (Inclisiran)30%

RNAi cholesterol-lowering drug partnered with Novartis

供应链关系

合作伙伴

Regeneron Pharmaceuticals

RNAi research collaboration

影响: Strategic R&D alliance

Eli Lilly and Company

Potential licensing discussions

影响: Pharma partnership potential

竞争对手

Moderna, Inc.

RNA-based therapeutic modalities

影响: Competing RNA platforms

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 Alnylam Pharmaceuticals, Inc. 的 AI 供应链分析。

企业信息

总部

Cambridge, Massachusetts, USA

成立时间

2002

员工人数

2,800+

官网

alnylam.com

行业概况 — 제약 / 바이오

行业新闻